Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer
Jessica J. Lin,Emily Chin,Beow Y. Yeap,Lorin A. Ferris,Vashine Kamesan,Inga T. Lennes,Lecia V. Sequist,Rebecca S. Heist,Mari Mino-Kenudson,Justin F. Gainor,Alice T. Shaw +10 more
Reads0
Chats0
TLDR
Careful consideration and monitoring for hepatotoxicity may be warranted in patients treated with crizotinib after ICI therapy, as sequential ICI and crizotoxicity treatment is associated with a significantly increased risk of hepatot toxicity.About:
This article is published in Journal of Thoracic Oncology.The article was published on 2019-01-01 and is currently open access. It has received 74 citations till now. The article focuses on the topics: Crizotinib & ROS1.read more
Citations
More filters
Journal ArticleDOI
The future of cancer immunotherapy: microenvironment-targeting combinations.
TL;DR: Two categories of approaches to the design of novel drugs and combination therapies are described: the first involves direct modification of the tumor, while the second indirectly enhances immunogenicity through alteration of the microenvironment.
Journal ArticleDOI
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
TL;DR: In this article , the authors summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies, and focused on the advances of αPD- 1/PD L 1-based immunomodulatory strategies in clinical studies.
Journal ArticleDOI
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
TL;DR: In this paper , the authors summarized the synergistic antitumor efficacies and mechanisms of α-PD-1/PD-L1 in combination with other therapies, and focused on the advances of αPD- 1/PD L 1-based immunomodulatory strategies in clinical studies.
Journal ArticleDOI
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
TL;DR: A comprehensive review of the current standards of care for targeted therapies in lung cancer with driver molecular alterations can be found in this article , where the authors discuss the importance of diagnostic molecular testing, intracranial efficacy of novel therapies, optimal sequencing of therapies, role for targeted therapy in early stage disease, and future directions for precision oncology approaches to understand tumor evolution and therapeutic resistance are also discussed.
Journal ArticleDOI
Application of magnetic nanoparticles in nucleic acid detection
Congli Tang,Ziyu He,Hongmei Liu,Yuyue Xu,Hao Huang,Gaojian Yang,Ziqi Xiao,Song Li,Hongna Liu,Yan Deng,Yan Deng,Zhu Chen,Hui Chen,Nongyue He +13 more
TL;DR: In this paper, the application of magnetic nanoparticles in nucleic acid detection was reviewed, based on the above, the authors showed that magnetic particles have good dispersion, high surface area, low cost, easy separation in buffer systems and signal detection.
References
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Flávia De Angelis,Manuel Domine,Philip Clingan,Maximilian J. Hochmair,Steven Francis Powell,Susanna Y.-S. Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Belén Rubio-Viqueira,Silvia Novello,Takayasu Kurata,Jhanelle E. Gray,John Vida,Ziwen Wei,J. Yang,Harry Raftopoulos,M. Catherine Pietanza,Marina Chiara Garassino +28 more
TL;DR: In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum‐based drug resulted in significantly longer overall survival and progression‐free survival than chemotherapy alone.
Journal ArticleDOI
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw,Dong Wan Kim,Kazuhiko Nakagawa,Takashi Seto,Lucio Crinò,Myung-Ju Ahn,Tommaso De Pas,Benjamin Besse,Benjamin Solomon,Fiona H Blackhall,Yi-Long Wu,Michael Thomas,Kenneth J. O'Byrne,Denis Moro-Sibilot,D. Ross Camidge,Tony Mok,Vera Hirsh,Gregory J. Riely,Shrividya Iyer,V. Tassell,Anna Polli,Keith D. Wilner,Pasi A. Jänne +22 more
TL;DR: Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement and greater improvement in global quality of life with crizotinIB than with chemotherapy.
Journal ArticleDOI
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Sai-Hong Ignatius Ou,Yung-Jue Bang,D. Ross Camidge,Benjamin Solomon,Ravi Salgia,Gregory J. Riely,Marileila Varella-Garcia,Geoffrey I. Shapiro,Daniel B. Costa,Robert C. Doebele,Long P. Le,Zongli Zheng,Zongli Zheng,Weiwei Tan,Patricia Stephenson,S. Martin Shreeve,L. Tye,James G. Christensen,Keith D. Wilner,Jeffrey W. Clark,A. John Iafrate +21 more
TL;DR: Crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC, and ROS1 rearrangement defines a second molecular subgroup of NSCLCs for which crizotin ib is highly active.
Journal ArticleDOI
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
D. Ross Camidge,Yung-Jue Bang,Eunice L. Kwak,A. John Iafrate,Marileila Varella-Garcia,Stephen B. Fox,Gregory J. Riely,Benjamin Solomon,Sai-Hong Ignatius Ou,Dong Wan Kim,Ravi Salgia,Panagiotis Fidias,Jeffrey A. Engelman,Leena Gandhi,Pasi A. Jänne,Daniel B. Costa,Geoffrey I. Shapiro,Patricia LoRusso,Katherine Ruffner,Patricia Stephenson,Yiyun Tang,Keith D. Wilner,Jeffrey W. Clark,Alice T. Shaw +23 more
TL;DR: Crizotinib is well tolerated with rapid, durable responses in patients with ALK-positive NSCLC and there seems to be potential for ongoing benefit after initial disease progression in this population, but a more formal definition of ongoing benefit in this context is needed.
Related Papers (5)
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Leena Gandhi,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,Flávia De Angelis,Manuel Domine,Philip Clingan,Maximilian J. Hochmair,Steven Francis Powell,Susanna Y.-S. Cheng,Helge Bischoff,Nir Peled,Francesco Grossi,Ross Jennens,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Belén Rubio-Viqueira,Silvia Novello,Takayasu Kurata,Jhanelle E. Gray,John Vida,Ziwen Wei,J. Yang,Harry Raftopoulos,M. Catherine Pietanza,Marina Chiara Garassino +28 more
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski,Robert M. Jotte,Federico Cappuzzo,Francisco Orlandi,Daniil Stroyakovskiy,Naoyuki Nogami,Delvys Rodriguez-Abreu,Denis Moro-Sibilot,Christian A. Thomas,Fabrice Barlesi,Gene Grant Finley,Claudia Kelsch,Anthony Lee,Shelley Coleman,Yu Deng,Yijing Shen,Marcin Kowanetz,Ariel Lopez-Chavez,Alan Sandler,Martin Reck +19 more